Children's Mercy Kansas City

SHARE @ Children's Mercy
Clinical Practice Guidelines

Quality Improvement and Clinical Safety

2-2016

Croup
Children's Mercy Kansas City

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/clinical_guidelines
Part of the Pediatrics Commons

These guidelines do not establish a standard of care to be followed in every case. It is
recognized that each case is different and those individuals involved in providing health care are
expected to use their judgment in determining what is in the best interests of the patient based
on the circumstances existing at the time. It is impossible to anticipate all possible situations
that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.

February 29, 2016
Children’s Mercy Hospitals and Clinics
Evidence Based Practice Clinical Practice Guide

Outpatient Croup

The Office of Evidence Based Practice, 2015
Center of Clinical Effectiveness

1

February 29, 2016
Inpatient Croup

The Office of Evidence Based Practice, 2015
Center of Clinical Effectiveness

2

February 29, 2016
Epidemiology:
Croup affects:
•

Children < 6 years old

•

The peak incidence is at ages 6-36 months

•

It is one and a half times more common in boys than girls

•

It is uncommon in adolescents and infants < 3 months old.

•

It is rare in adults.

The prevalence of croup occurs in about 5% of children between ages 12 and 24 months and is most prevalent in
fall and early winter. Risk factors include upper respiratory infection (URI), especially parainfluenza virus
infection, age < 6 years, especially ages 6-36 months, and inadequate immunization. Family history is a risk factor
for croup (Woods, 2015).
Definition:
• Croup is a common childhood respiratory illness characterized by barking cough, often accompanied by
inspiratory stridor, hoarseness, and respiratory distress.
• Croup is usually associated with viral infection (Woods, 2015).
Objective of Guideline: The objective of this guideline is to standardize and improve care for otherwise healthy
children diagnosed with croup in the Emergency Departments(ED)/Urgent Care Centers (UCC), outpatient
settings, and inpatient medical units.
Target Users: Physicians, nurse practitioners, and staff nurses caring for children with croup in EDs, UCCs,
outpatient settings, and inpatient settings.
Guideline Inclusion Criteria:
Previously healthy patients (ages 6 months to 6 years) with the clinical presentation consistent with the diagnosis
of croup.
Guideline Exclusion Criteria:
• Toxic appearance
• Complex medical co-morbidities
• Hypotonia or neuromuscular disease
• Symptoms suggestive of an alternative diagnosis: (a) expiratory wheeze, (b) drooling or difficulty
swallowing, (c) prolonged or recurrent stridor, (d) poor response to treatment
• Known airway abnormalities: (a) vocal cord paralysis, (b) subglottic stenosis, (c) tracheomalacia, (d)
laryngomalacia, (e) history of vascular ring or tracheoesophageal fistula
Clinical Questions Answered by Guideline:
1. In children with croup, is prednisolone as efficacious as dexamethasone to resolve symptoms?
2. In children with croup, what is the recommended dose, frequency, and route of administration (oral vs.
IM) of dexamethasone and prednisolone?
3. In children with croup, how long should observation be post racemic epinephrine dose and is there a
rebound effect?
4. In children with croup, what are the criteria for admission?
5. In children with croup, are x-rays needed in the management of croup?
6. In children with croup, when is an ENT consultation necessary?
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7. Are there valid and reliable croup scores to classify children with croup?
Practice Recommendations:
1. Evaluation
a. The definition of croup severity was determined from existing guidelines (Seattle Children’s
Hospital (2012), Children’s Hospital of Philadelphia (2014), Children’s Hospital of Colorado
(2011)) and expert opinion.
i. Mild croup is defined as barky cough, no stridor at rest, no tachypnea, no retractions, and
no mental status changes.
ii. Moderate croup is defined as stridor at rest, mild tachypnea, mild retractions, and no
mental status changes.
iii. Severe croup is defined as stridor at rest, severe tachypnea, severe retractions, mental
status changes, and/or hypoxia.
b. Croup scores
i. There is no validated tool to assess croup severity in the clinical setting.
ii. The Westley Croup Score is the most commonly referenced scoring tool for croup
severity (Westley, Cotton, & Brooks, 1978). The original study measured the clinical
response of nebulized racemic epinephrine versus saline. It didn’t aim to create a
prognostic scoring system.
2. Ambulatory Treatment Settings
a. Mild Croup: Glucocorticosteroids are recommended for mild croup. Dexamethasone is the first
line glucocorticoid therapy for croup(Russell et al., 2011).
i. Dexamethasone 0.6mg/kg (max dose 12mg) given once orally or intramuscularly.
1. There are some small studies showing that a dexamethasone dose of 0.15mg/kg
may be as effective as a dose of 0.6mg/kg (Russell, Liang, O'Gorman, Johnson,
& Klassen, 2011).
2. Only one dose of dexamethasone is recommended based on expert opinion.
a. There are no RCTs comparing single dose versus multiple dose
dexamethasone for croup.
3. There is no difference in PO versus IM dexamethasone (Russell et al., 2011).
ii. Prednisolone 2mg/kg/day for 3 days.
1. Multi-dose prednisolone is just as efficacious as dexamethasone. Based on a few
small studies, there may be increased readmission rate with prednisolone (Russell
et al., 2011). Although, these studies compared single dose dexamethasone vs. a
single dose prednisolone. Garbutt et al. (2013) showed no difference in
readmission rate when a single dose dexamethasone is compared to multiple
doses of prednisolone.
iii. There is no evidence that a combination of dexamethasone and prednisolone improve
croup (Russell et al., 2011).
b. Moderate/Severe Croup:
i. All patients should get dexamethasone 0.6mg/kg (max dose 12mg) given once orally or
intramuscularly if not previously given.
ii. Racemic epinephrine (0.5ml of 2.25%)
1. There is no evidence of a rebound effect resulting in increase in croup severity
with racemic epinephrine treatment (Bjornson et al., 2011).
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2. Repeat racemic epinephrine dose if a poor response to the first treatment or
respiratory symptoms recur after an initial good response (Bjornson et al., 2011).
3. Discharge from Ambulatory Setting
a. Discharge criteria were developed based on expert opinion.
b. No stridor at rest, tachypnea, intercostal retractions, or other signs of increased work of breathing.
c. Received one dose of dexamethasone.
d. Observed for at least 2 hours if racemic epinephrine has been administered.
e. No other indications for hospitalization.
f. The patient is able to return to the ED/UCC if symptoms return.
4. Admission
a. Admission criteria were developed based on expert opinion and guideline review.
b. Absolute Admission:
i. Moderate croup: failed two doses of racemic epinephrine treatment.
ii. Severe croup: failed one racemic epinephrine treatment.
iii. Patient not otherwise meeting discharge criteria.
c. Relative Admission:
i. Inadequate access to medical care (lives long distance from hospital, transportation
barriers) and concerns for inadequate observation at home or follow-up.
ii. Significant parental anxiety.
iii. Recurrent ED visit within 24hours.
5. Inpatient
a. All patients should get dexamethasone 0.6mg/kg (max dose 12mg) given once orally or
intramuscularly, if not previously given. Racemic epinephrine should be given PRN.
b. Oxygen is indicated for cyanosis, hypoxia (oxygen saturation < 90% on room air), or respiratory
distress.
c. Signs of impending respiratory failure: (a) poor respiratory effort, (b) severe retractions, (c) poor
response to racemic epinephrine, (d) listless or decreased level of consciousness, (e)
cyanosis/hypoxemia.
d. Consider bacterial tracheitis, epiglottitis, or retropharyngeal abscess in children who appear toxic,
either before or after racemic epinephrine.
e. Children who do not respond to racemic epinephrine may have an alternative diagnosis and need
further workup.
i. Other diagnosis: (a) bacterial tracheitis, (b) retropharyngeal abscess, (c) allergic reaction,
(d) foreign body, (e) epiglottitis.
f. Consider emergent airway management and ENT consultation if the patient is still having stridor
at rest after 3 or more doses of racemic epinephrine.
g. Consider heliox for patients needing repeat doses of racemic epinephrine (Moraa, Sturman,
McGuire, & van Driel, 2013).
6. Inpatient Discharge Criteria
a. > 2hours since last racemic epinephrine.
b. No stridor at rest, tachypnea, intercostal retractions, or other signs of increased work of breathing.
c. Able to talk and feed without difficulty.
d. The patient is able to return to the ED/UCC if symptoms return.
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1. Not Routinely Recommended based on expert opinion.
a. Humidified air.
i. There is no RCT evidence that supports the use of humidified air (Johnson, 2014).
b. X-ray
i. There is no evidence that radiographs are necessary in a typical presentation of croup that
responds to therapy. Consider for suspected alternative diagnosis.
c. ENT consult
i. There is no evidence that an ENT consult is necessary in a typical presentation of croup that
responds to therapy. Consider for suspected alternative diagnosis.
d. Viral testing
i. There is no evidence that laboratory testing improves croup outcomes. Consider for suspected
alternative diagnosis.
Outcome Measures:
• Number of admissions with primary croup diagnosis.
• Length of stay for the hospitalized patient.
• X-rays ordered with primary diagnosis of croup.
• Number of doses of racemic epinephrine per patient with primary diagnosis of croup
• Steroids given (prednisolone versus dexamethasone vs both)
• Prescriptions
Potential Cost Implications:
• Patient savings related to a decrease in x-rays, ENT consults, and medications given or prescribed.
• Decreased admissions.
Guideline Preparation: This guideline was prepared by The Office of Evidence Based Practice (EBP) in
collaboration with content experts at Children’s Mercy Hospitals and Clinics. Development of this guideline
supports the Department of Clinical Effectiveness’s initiative to promote care standardization that builds a culture
of quality and safety that is evidenced by measured outcomes. If a conflict of interest is identified the conflict will
be disclosed next to the team members name.
Croup Team Members:
• Courtney Butler, MLS, Librarian
• Ashley Daily, MD, Physician
• DeeJo Miller, Family Centered Care Coordinator
• Amanda Montalbano, MD, MPH, Physician, QBS
• Steven Schebler, PharmD, BCPS, Clinical Pharmacist
• Erin Scott, DO, Physician
• Nirav Shastri, MD, Director, IT and Scholarly Activities, CM South ED
• Kathryn Spectorsky, MD, Pediatric Resident
• Katie Stangler, RN, MSN, APRN, CPNP, CCRN, Critical Care Nurse Practitioner
• Donna Wyly, RN, MSN, APRN, PC-PNP, CPNP-AC, ONC, Education Coordinator, Emergency &
Urgent Care Services
Office of EBP Team Members responsible for reviewing, synthesizing, and developing the synopsis and the
specific care questions were:
• Jeffrey Michael, D.O., FAAP, EBP Medical Director
• Jarrod Dusin, MS, RD, LD, CNSC Team Facilitator
• Jacqueline A. Bartlett, PhD, RN, EBP Director
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•

Nancy Allen, MS, MLS, RD, LD, EBP Program Manager

Guideline development funded by: Departmental funding
Development Process:
We initially performed a filtered search of the literature that included systematic reviews, meta-analyses, and
published guidelines. Twenty guidelines were evaluated using the AGREE tool to determine quality of the
guidelines. Three guidelines ("Croup Clinical Care Guidline: Age 6 Months to 3 Years," 2011; "Croup v.1.1: ED
Management, Inpatient Management," 2012; "ED Pathway for the Evaluation/Treatment of the Child with
Croup," 2014) were selected based on their AGREE score and were used as our development guides with
modifications. Four Cochrane meta-analysis and systematic reviews (Bjornson et al., 2011; Moore & Little, 2006;
Moraa et al., 2013; Russell et al., 2011) were also included in the development of this guideline. A further
literature search was preformed to look for any new research on the subject of our questions.
The review summary documents the following steps:
1. Review of existing internal and external guidelines and standards
External guidelines: Croup (2012). Seattle Children’s Hospital.
Croup (2014). Children’s Hospital of Philadelphia.
Croup (2011). Children’s Hospital of Colorado.
2. Review preparation
a. PICOT questions established
b. Team leaders confirmed search terms used
3. Databases searched
a. AHRQ National Guideline Clearinghouse
b. Medline
c. Cochrane
d. CINAHL
4. Critically analyze the evidence
a. Guidelines
i.
AGREE criteria were used to analyze published clinical guidelines
b. Literature
i.
GRADE criteria evaluated the literature based on:
1. The balance between desirable and undesirable effects
2. Patient values and preferences
3. Resource utilization
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The table below defines how the quality of the evidence is rated and how the recommendation is
established based on the type of evidence:
Quality
Type of Evidence
High
Consistent evidence from well-performed RCTs or
exceptionally strong evidence from unbiased observational
studies.
Moderate
Evidence from RCTs with important limitations
(inconsistent results, methodological flaws, indirect
evidence, or imprecise results) or unusually strong evidence
from unbiased observational studies.
Low
Evidence for at least 1 critical outcome from observational
studies, from RCTs with serious flaws or indirect evidence.
Very Low
Evidence for at least 1 of the critical outcomes from
unsystematic clinical observations or very indirect
evidence.
Recommendation
Type of Evidence
Strong
Desirable effects clearly outweigh undesirable effects or
vice versa
Weak
Desirable effects closely balanced with undesirable effects
5. Recommendations for the guideline were developed by a consensus process incorporating the three principles
of EBP (current literature, content experts, and patient and family preference [when possible])
Approval Process: Guidelines are reviewed and approved by an internal reviewer, Tiffany Addington MD,
external reviewer, Erika Sidney MD (Children’s Hospital Colorado), Content Expert Team, the Office of EBP,
and other appropriate hospital committees as deemed suitable for the guidelines intended use. Guidelines are
reviewed and updated as necessary every 3 years within the Office of EBP at CMH&C. Content expert teams will
be involved with every review and update.
Disclaimer: When evidence is lacking or inconclusive, options in care are provided in the guideline and the
power plans that accompany the guideline.
These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is
different and those individuals involved in providing health care are expected to use their judgment in
determining what is in the best interests of the patient based on the circumstances existing at the time.
It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly
these guidelines should guide care with the understanding that departures from them may be required at times.
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Question: (1) In children with croup, is prednisolone as efficacious as dexamethasone in treatment?
Question Originator: Croup Clinical Practice Guideline Work Group.
Croup CPG Team Recommendations: Multi-dose prednisolone is just as efficacious as dexamethasone. Based on a few small studies from a Cochrane metaanalysis, there may be increased readmission rate with prednisolone; although, these studies compared single dose dexamethasone vs. a single dose prednisolone
(Russell et al., 2011). Garbutt (2013) showed no difference in readmission rate when a single dose dexamethasone is compared to multiple doses of prednisolone.
This statement is in agreement with the guidelines we reviewed.
EBP Scholar’s responsible for analyzing the literature:
Teresa Bontrager, RN, CPEN, BSME
Jamie Cailteux, RN, BSN, CPN
Jennifer Foley, RT(R)(N) CNMT
Anne Holmes, RN, MSN, MBA-HC, CCR
Audrey Kennedy, PharmD, BCPS
Joyce McCollum, RN, CNOR
Laura McDonald, RN
Carrie Novak, MS, RD, CSP, LD
Kim Robertson, MBA, MT-BC
Amy Scott, RN, BSN, CPN
Dee Smith, LCSW
Donna Wyly MSN, RN, PC-PNP, CPNP-AC, ONC
Search Strategy and Results:
Search: ("Croup"[Mesh] OR croup OR "Parainfluenza Virus 2, Human"[Mesh] OR laryngotracheobronchitis OR laryngotracheitis) AND
((("Prednisolone"[Mesh] OR prednisolone OR prednisone) AND ("Dexamethasone"[Mesh] OR dexamethasone OR decadron OR oradexon OR efficac* OR
effectiv*)) OR glucocorticoid* OR "Glucocorticoids"[Mesh] OR corticosteroid*) Filters: From 2010/01/01
Guidelines and studies included in this review:
Croup (2012). Seattle Children’s Hospital
Croup (2014) Children’s Hospital of Philadelphia
Croup (2011) Children’s Hospital of Colorado
Russell, 2011
Garburtt, 2013
Guidelines and studies not included in this review with rationale for exclusion:
Nottingham Children's Hospital 2012 – Recommended unavailable medications
Petrocheilou 2014 – Review article

The Office of Evidence Based Practice, 2015
Center of Clinical Effectiveness

9

February 29, 2016
Method Used for Appraisal and Synthesis:
AGREE II was used to evaluate the included Guidelines. The Cochrane Collaborative computer program, Review Manager (RevMan 5.3).
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Garbutt 2013
Methods
Participants

RCT
Setting: 10 pediatric offices of PCPs in the St. Louis, Missouri area
Randomized: Treatment group (prednisolone n= 41), Control group (dexamethasone n=46)
Age: Prednisolone group: 2.67±1.43, Dexamethasone group: 3.11±1.58
Completed: 40 completed for prednisolone and 45 completed for dexamethasone
Gender: Prednisolone group: 28 (61%) male/Dexamethasone group: 28 (68%) male.
Inclusion criteria: Children 1-8 years of age with croup symptoms for less than or equal to 48 hours with a clinical diagnosis of mild or
moderate croup at a participating site.
Exclusion criteria: Patients were excluded if they were diagnosed with severe croup or impending respiratory failure by the PCP; or had
prior treatment with epinephrine or oral corticosteroids for this croup episode; or symptoms or signs suggesting another cause of stridor;
or chronic respiratory disease including asthma; or a known contraindication to systemic steroid use. Also excluded were children if
parent in attendance would not be in the same household as the child for the subsequent 4 days, could not participate in telephone followup interviews, or was not English speaking.
Power analysis: A target sample of 100 patients per group was determined to be needed to estimate event rates and the width of the 95%
confidence interval. Adequate prior information to estimate the need for additional health care in the prednisolone group and, therefore,
to calculate statistical power, was not available. All analysis adhered to the intention-to-treat principle, and a probability of P < .05 was
used to establish statistical significance.

Interventions
Outcomes

Prednisolone group: 2 mg/kg (maximum 60 mg/d) once a day for 3 days
Dexamethasone group: 0.6 mg/kg (maximum 18mg) followed by 2 days of placebo comparable in appearance, smell, and taste
There was no difference in the 2 groups in reported additional healthcare for croup in the 11 days following the index visit (prednisolone,
7%, 95% CI= 1.5% to 19.9%; Dexamethasone, 2%, 95% CI=0.0% to 11.5%; P=.34)
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Risk of bias table
Bias
Random sequence
generation (selection bias)

Scholar
Judgment
Low Risk

Support for judgment
Computer-generated random numbers determined how the two treatments were allocated to the consecutively
numbered study drug packages at each site.
Randomized blocks were used to assign subjects to treatment groups, with randomization stratified by site.

Allocation concealment
(selection bias)

Low Risk

The drug formulation (completed by licensed pharmacist in another state) ensured the volume of the weight-based
dose was equivalent for each medication

Blinding of participants and
personnel (performance
bias)

Low Risk

Due to outside licensed pharmacist mixing drug and computer generated allocation of drugs, blinding of
participants and personnel was ensured.

Blinding of outcome
assessment (detection bias)

Low Risk

Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

Incomplete outcome data
(attrition bias)

Low Risk

Plausible effect size among missing outcomes not enough to have a clinically relevant impact on observed effect
size (both groups lost one participant in follow-up).

Selective reporting
(reporting bias)

Low Risk

All study protocol is available and all of the study's pre-specified outcomes have been reported in a pre-specified
way.

Other bias

Unclear Risk

Drug mixing involved 2mg/kg of prednisolone and 0.6mg/kg of dexamethasone. It is unclear and not included in
document how this was completed to blind study personnel as the physician had to draw the correct dose per child's
weight in the office and then also prepare correct dose for parent to administer at home.

The Office of Evidence Based Practice, 2015
Center of Clinical Effectiveness

12

February 29, 2016
Figure 1: Dexamethasone versus Prednisolone, Outcome Return visits and /or (re)admissions by inpatient/outpatient.

*Figure recreated using Russell (2011).
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Question: (2) In children with croups, what is the recommended dose, frequency, and route of administration (oral vs. IM) of dexamethasone and
prednisolone?
Question Originator: Croup Clinical Practice Guideline Work Group.
Croup CPG Team Recommendations: Based on very poor evidence from a Cochrane meta-analysis, there is no difference in PO and IM
dexamethasone (Russell, 2011). There are a few small studies showing that a dexamethasone dose of 0.15mg/kg may be as effective as a dose of
0.6mg/kg (Russell, 2011). Only one dose of dexamethasone is recommended based on expert opinion. There are no RCTs comparing single dose versus
multiple dose dexamethasone for croup. This statement is in agreement with the guidelines we reviewed.
EBP Scholar’s responsible for analyzing the literature:
Teresa Bontrager, RN, CPEN, BSME
Jamie Cailteux, RN, BSN, CPN
Jennifer Foley, RT(R)(N) CNMT
Anne Holmes, RN, MSN, MBA-HC, CCR
Audrey Kennedy, PharmD, BCPS
Joyce McCollum, RN, CNOR
Laura McDonald, RN
Carrie Novak, MS, RD, CSP, LD
Kim Robertson, MBA, MT-BC
Amy Scott, RN, BSN, CPN
Dee Smith, LCSW
Donna Wyly MSN, RN, PC-PNP, CPNP-AC, ONC
Search Strategy and Results: ("Croup"[Mesh] OR croup OR "Parainfluenza Virus 2, Human"[Mesh] OR laryngotracheobronchitis OR
laryngotracheitis) AND ("Prednisolone/administration and dosage"[Mesh] OR "Dexamethasone/administration and dosage"[Mesh] OR
"Glucocorticoids/administration and dosage"[Mesh] OR ((dexamethasone OR decadron OR oradexon OR prednisolone OR prednisone OR
glucocorticoid* OR corticosteroid*) AND (dose OR dosage OR administration OR oral OR intramuscular))) Filters: From 2010/01/01
Guidelines and studies included in this review:
Croup (2012). Seattle Children’s Hospital
Croup (2014) Children’s Hospital of Philadelphia
Croup (2011) Children’s Hospital of Colorado.
Russel 2011
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Guidelines and studies not included in this review with rationale for exclusion:
Nottingham Children's Hospital 2012 – recommended unavailable medications.
Dobrovoliac 2012 , The study only looked at croup score for 15mg/kg oral dexamethasone.
Petrocheilou 2014, Review article.
Method Used for Appraisal and Synthesis:
AGREE was used to evaluate the included Guidelines. The Cochrane Collaborative computer program, Review Manager (RevMan 5.3).
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Figure 2. Comparison Oral versus intramuscular dexamethasone, Outcome Return visits and /or (re)admissions by inpatinet/outpatient.

*Figure recreated using Russell (2011).

Figure 3. Comparison dexamethasone 0.6mg/kg versus dexamethasone 0.15mg/kg, Outcome Return visits and/or (re)admissions by inpatient/outpatient

*Figure recreated using Russell (2011).
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Figure 4. Comparison dexamethasone 0.6mg/kg versus dexamethasone 0.3mg/kg, Outcome Return visits and/or (re)admissions by inpatient/outpatient

*Figure recreated using Russell (2011).

Figure 5. Comparison dexamethasone 0.3mg/kg versus dexamethasone 0.15mg/kg, Outcome Return visits and/or (re)admissions by inpatient/outpatient

*Figure recreated using Russell (2011).
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Question (3): In children with croup, how long should observation be post racemic epinephrine dose and is there a rebound effect?
Question Originator: Croup Clinical Practice Guideline Work Group.
Croup CPG Team Recommendations: Observation should be for two hours post racemic epinephrine based on expert opinion. There is no evidence of a
rebound effect resulting in increase in croup severity with racemic epinephrine treatment (Bjornson, 2011).This statement is in agreement with the guidelines we
reviewed.
EBP Scholar’s responsible for analyzing the literature:
Teresa Bontrager, RN, CPEN, BSME
Jamie Cailteux, RN, BSN, CPN
Jennifer Foley, RT(R)(N) CNMT
Anne Holmes, RN, MSN, MBA-HC, CCR
Audrey Kennedy, PharmD, BCPS
Joyce McCollum, RN, CNOR
Laura McDonald, RN
Carrie Novak, MS, RD, CSP, LD
Kim Robertson, MBA, MT-BC
Amy Scott, RN, BSN, CPN
Dee Smith, LCSW
Donna Wyly MSN, RN, PC-PNP, CPNP-AC, ONC
Search Strategy and Results:
Search: ("Croup"[Mesh] OR croup OR "Parainfluenza Virus 2, Human"[Mesh] OR laryngotracheobronchitis OR laryngotracheitis) AND
("Racepinephrine"[Mesh] OR "Epinephrine"[Mesh] OR racemic OR epinephrin* OR rebound) Filters: From 2013/01/01
Guidelines and studies included in this review:
Croup (2012). Seattle Children’s Hospital
Croup (2014) Children’s Hospital of Philadelphia
Croup (2011) Children’s Hospital of Colorado.
Bjornson, 2011
Guidelines and studies not included in this review with rationale for exclusion:
Nottingham Children's Hospital 2012 – recommended unavailable medications.
Petrocheilou 2014, Review article.
Method Used for Appraisal and Synthesis:
AGREE was used to evaluate the included Guidelines. The Cochrane Collaborative computer program, Review Manager (RevMan 5.3).
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Question: (4) In children with croup, what are the criteria for admission?
Croup CPG Team Recommendations: Based on expert opinion, patients with moderate croup should be admitted after two failed doses of racemic epinephrine
treatment. Patients with severe croup should be admitted after one failed racemic epinephrine treatment. Patients should be admitted if not otherwise meeting
discharge criteria. This statement is in agreement with the guidelines we reviewed.
EBP Scholar’s responsible for analyzing the literature:
Teresa Bontrager, RN, CPEN, BSME
Jamie Cailteux, RN, BSN, CPN
Jennifer Foley, RT(R)(N) CNMT
Anne Holmes, RN, MSN, MBA-HC, CCR
Audrey Kennedy, PharmD, BCPS
Joyce McCollum, RN, CNOR
Laura McDonald, RN
Carrie Novak, MS, RD, CSP, LD
Kim Robertson, MBA, MT-BC
Amy Scott, RN, BSN, CPN
Dee Smith, LCSW
Donna Wyly MSN, RN, PC-PNP, CPNP-AC, ONC
Search Strategy and Results:
Search: ("Croup"[Mesh] OR croup OR "Parainfluenza Virus 2, Human"[Mesh] OR laryngotracheobronchitis OR laryngotracheitis) AND ("Patient
Admission"[Mesh] OR ((admission OR hospitaliz* OR inpatient) AND criteri*)) ("Croup"[Mesh] OR croup OR "Parainfluenza Virus 2, Human"[Mesh] OR
laryngotracheobronchitis OR laryngotracheitis) AND ("Patient Discharge"[Mesh] OR discharg* OR "Length of Stay"[Mesh])
Guidelines and studies included in this review:
Croup (2012). Seattle Children’s Hospital
Croup (2014) Children’s Hospital of Philadelphia
Croup (2011) Children’s Hospital of Colorado.
Guidelines and studies not included in this review with rationale for exclusion:
Nottingham Children's Hospital 2012 – recommended unavailable medications.
Petrocheilou 2014 – Review article.
Method Used for Appraisal and Synthesis:
AGREE was used to evaluate the included Guidelines. The Cochrane Collaborative computer program, Review Manager (RevMan 5.3).
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Question: (5) In children, are x-rays needed in the management of croup?
Question Originator: Croup Clinical Practice Guideline Work Group.
Croup CPG Team Recommendations: Based on expert opinion, radiographs are not necessary in croup with typical presentation that responds to therapy. This
statement is in agreement with the guidelines we reviewed.
EBP Scholar’s responsible for analyzing the literature:
Teresa Bontrager, RN, CPEN, BSME
Jamie Cailteux, RN, BSN, CPN
Jennifer Foley, RT(R)(N) CNMT
Anne Holmes, RN, MSN, MBA-HC, CCR
Audrey Kennedy, PharmD, BCPS
Joyce McCollum, RN, CNOR
Laura McDonald, RN
Carrie Novak, MS, RD, CSP, LD
Kim Robertson, MBA, MT-BC
Amy Scott, RN, BSN, CPN
Dee Smith, LCSW
Donna Wyly MSN, RN, PC-PNP, CPNP-AC, ONC
Search Strategy and Results: Search: ("Croup"[Mesh] OR croup OR "Parainfluenza Virus 2, Human"[Mesh] OR laryngotracheobronchitis OR
laryngotracheitis) AND ("Radiography, Thoracic"[Mesh] OR "Thorax/radiography"[Mesh] OR "Neck/radiography"[Mesh] OR "Tomography, X-Ray"[Mesh]
OR "Tomography, X-Ray Computed"[Mesh] OR x-ray*)
Guidelines and studies included in this review:
Croup (2012). Seattle Children’s Hospital
Croup (2014) Children’s Hospital of Philadelphia
Croup (2011) Children’s Hospital of Colorado.
Guidelines and studies not included in this review with rationale for exclusion:
Nottingham Children's Hospital 2012 – recommended unavailable medications.
Petrocheilou 2014 – Review article.
Method Used for Appraisal and Synthesis:
AGREE was used to evaluate the included Guidelines. The Cochrane Collaborative computer program, Review Manager (RevMan 5.3).
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Question: (6) In children with, when is an ENT consultation necessary?
Question Originator: Croup Clinical Practice Guideline Work Group.
Croup CPG Team Recommendations: Based on expert opinion, ENT consultations are not necessary in croup with typical presentation that responds to
therapy. This statement is in agreement with the guidelines we reviewed.
EBP Scholar’s responsible for analyzing the literature:
Teresa Bontrager, RN, CPEN, BSME
Jamie Cailteux, RN, BSN, CPN
Jennifer Foley, RT(R)(N) CNMT
Anne Holmes, RN, MSN, MBA-HC, CCR
Audrey Kennedy, PharmD, BCPS
Joyce McCollum, RN, CNOR
Laura McDonald, RN
Carrie Novak, MS, RD, CSP, LD
Kim Robertson, MBA, MT-BC
Amy Scott, RN, BSN, CPN
Dee Smith, LCSW
Donna Wyly MSN, RN, PC-PNP, CPNP-AC, ONC
Search Strategy and Results:
Search: ("Croup"[Mesh] OR croup OR "Parainfluenza Virus 2, Human"[Mesh] OR laryngotracheobronchitis OR laryngotracheitis) AND
("Otolaryngology"[Mesh] OR otolaryngolog* OR ent)
Guidelines and studies included in this review:
Croup (2012). Seattle Children’s Hospital
Croup (2014) Children’s Hospital of Philadelphia
Croup (2011) Children’s Hospital of Colorado.
Guidelines and studies not included in this review with rationale for exclusion:
Nottingham Children's Hospital 2012 – recommended unavailable medications.
Petrocheilou 2014 – Review article.
Method Used for Appraisal and Synthesis:
AGREE was used to evaluate the included Guidelines. The Cochrane Collaborative computer program, Review Manager (RevMan 5.3).
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Question: (7) Are there valid and reliable croup scores to classify children with croup?
Question Originator: Croup Clinical Practice Guideline Work Group.
Croup CPG Team Recommendations: There is no validated tool to assess croup severity in the clinical setting.

EBP Scholar’s responsible for analyzing the literature:
Teresa Bontrager, RN, CPEN, BSME
Jamie Cailteux, RN, BSN, CPN
Jennifer Foley, RT(R)(N) CNMT
Anne Holmes, RN, MSN, MBA-HC, CCR
Audrey Kennedy, PharmD, BCPS
Joyce McCollum, RN, CNOR
Laura McDonald, RN
Carrie Novak, MS, RD, CSP, LD
Kim Robertson, MBA, MT-BC
Amy Scott, RN, BSN, CPN
Dee Smith, LCSW
Donna Wyly MSN, RN, PC-PNP, CPNP-AC, ONC
Search Strategy and Results: Search: ("Croup"[Mesh] OR croup OR "Parainfluenza Virus 2, Human"[Mesh] OR laryngotracheobronchitis OR
laryngotracheitis) AND (("Severity of Illness Index"[Mesh] AND (score* OR scoring)) OR "croup score" OR "croup scores" OR "croup scoring")

Guidelines and studies included in this review:
Croup (2012). Seattle Children’s Hospital
Croup (2014) Children’s Hospital of Philadelphia
Croup (2011) Children’s Hospital of Colorado.
Guidelines and studies not included in this review with rationale for exclusion:
Nottingham Children's Hospital 2012 – recommended unavailable medications.
Petrocheilou 2014 – Review article.
Westly CR (1978), This study measured the clinical response of nebulized racemic epinephrine versus saline. It didn’t aim to create a prognostic scoring system.
Method Used for Appraisal and Synthesis:
AGREE was used to evaluate the included Guidelines. The Cochrane Collaborative computer program, Review Manager (RevMan 5.3).
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